Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

Finally, the number of opportunities in the biosimilars space is very high — there are more than 300 biologics in the market, ...

PTC Therapeutics has received FDA approval for a gene therapy to treat AADC deficiency, a rare genetic disorder that impairs ...

A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over ...

From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of ...

The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.

The global contract development and manufacturing organization ​ (CDMO), Samsung Biologics, announced this week that it has ...

The STOX Suite is a digital platform that standardizes the measurement of steroid-toxicity, enabling researchers and ...

Alentis’ Series D financing round this week, marks the largest ADC-related fundraising in Europe in 2024. Other notable ...